Highest-materiality recent filing
Net loss $24.5M in Q2 2026 vs $33.4M in Q2 2025; collaboration revenue $3.2M (down from $5.2M).
Voyager presents positive GLP tox data for tau gene therapy VY1706; plans H2 2026 dosing
GLP toxicology data for VY1706 showed favorable tolerability in NHPs with no adverse CNS or peripheral findings up to 5x10^13 vg/kg.
Voyager shareholders approve doubling authorized shares to 245M
Authorized capital stock increased from 125M to 245M; common stock from 120M to 240M, effective June 9, 2026.
FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's
VY1706 targets intra- and extracellular tau; IND cleared by FDA on June 1, 2026.
Voyager Q1 net loss $27.9M, cash $172M into 2028; VY1706 tau gene therapy on track for H2 dosing
Net loss $27.9M (Q1 2026) vs $31.0M (Q1 2025); revenue $2.6M down from $6.5M due to lower collaboration revenue.
Voyager Therapeutics CFO Nathan Jorgensen resigns; Robin Swartz named PFO, Amy Quinlan PAO
CFO Nathan Jorgensen, Ph.D. resigns effective May 8, 2026, to pursue new opportunity; no disagreement with company.
Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026
Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.
Chief Medical Officer Toby Ferguson resigns; CEO Sandrock takes over clinical leadership
Toby Ferguson, M.D., Ph.D., resigned as CMO effective Feb 20, 2026, to pursue a new opportunity.
Biogen's BIIB080 Phase II data expected mid-2026; Voyager's VY1706 gene therapy first-in-human in H2 2026.
Voyager Q3 net loss widens to $27.9M; cash runway into 2028; NeuroShuttle platform launched
Net loss of $27.9M (vs $9.0M in Q3 2024); collaboration revenue fell to $13.4M from $24.6M.
Company presented at Citi's 2025 Biopharma Back to School Conference on September 2, 2025.
Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028
Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.
Voyager stockholders approve 2025 stock plans, elect directors at annual meeting
Approved 2025 Stock Incentive Plan: 28.6M for, 11.3M against, 8.5M broker non-votes.
Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027
Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).
Voyager Therapeutics Q4 2024 net loss $34.5M; tau gene therapy VY1706 IND filing planned for 2026
Net loss $34.5M in Q4 2024 vs net income $56.4M in Q4 2023; full year net loss $65.0M vs income $132.3M.
Voyager delays SOD1 ALS IND filing; switches payload after NHP data; cash runway to mid-2027
VY9323 IND/CTA filing no longer expected mid-2025 due to need for alternate payload after 3-month NHP data.
Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025
Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.
Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones
Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.
Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025
Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.
Voyager Therapeutics appoints Nathan Jorgensen as CFO effective July 8, 2024
Jorgensen, 47, previously CFO of Vor Biopharma; will report to CEO Alfred Sandrock.
Voyager stockholders elect three Class III directors, approve say-on-pay, ratify auditor
Michael Higgins, Jude Onyia, and Nancy Vitale elected Class III directors until 2027.
First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.
Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027
Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.
CFO Peter Pfreundschuh resigns effective April 12, 2024; remains as Senior Financial Advisor until May 5, 2024.
Voyager Therapeutics names Toby Ferguson as Chief Medical Officer
Employment starts March 25, 2024; base salary $485,000, target bonus 40%.
Voyager Therapeutics reports Q4 net income $56.4M, pro-forma cash $431M, pipeline milestones
Q4 collaboration revenue $90.1M (vs -$1.6M YoY), net income $56.4M (vs loss $23.6M).
Voyager Therapeutics prices $100M public offering; closes $20M Novartis private placement
Public offering of 7,777,778 shares at $9.00/share and 3,333,333 pre-funded warrants at $8.999, gross proceeds ~$100M.
Voyager Therapeutics enters $100M upfront collaboration with Novartis for SMA and HD gene therapy
Voyager Therapeutics entered into a license and collaboration agreement with Novartis for AAV capsids for SMA and Huntington's disease programs, with $80M upfront payment and $20M stock purchase.
Voyager selects lead candidate for SOD1-ALS gene therapy; IND filing expected mid-2025
Lead candidate combines siRNA construct with IV-delivered TRACER capsid targeting SOD1-mutated ALS.
Voyager Q3 net loss $25.9M; advances VY-TAU01 IND, SOD1 ALS candidate selection by year-end
Net loss $25.9M in Q3 2023 vs net income $17.6M in Q3 2022; collaboration revenue fell to $4.6M from $41.1M.
Voyager Therapeutics expands leased space by ~61k SF; annual rent ~$4.9M starting June 2024
Total leased premises grows to 93,449 rentable SF (from ~32k SF) with addition of third floor.
Voyager Q2 net loss $22.2M, launches anti-Aβ gene therapy for Alzheimer's
Q2 2023 collaboration revenue $4.9M (up from $0.7M YoY); net loss $22.2M vs $19.1M YoY.
Voyager Therapeutics appoints Jacquelyn Fahey Sandell as Chief Legal Officer
Jacquelyn Fahey Sandell named CLO effective July 10, 2023; reports to CEO Alfred Sandrock.
Voyager Therapeutics stockholders elect three Class II directors at 2023 annual meeting
Elected Class II directors: Steven Hyman (20,552,674 for), James A. Geraghty (16,613,243 for), Alfred Sandrock (20,551,414 for); broker non-votes 8,405,461.
Voyager Therapeutics appoints George Scangos to Board of Directors
George Scangos, Ph.D., appointed as Class I director effective May 9, 2023, serving until 2025 annual meeting.
Voyager Therapeutics Q1 net income $124M on $150.5M collaboration revenue; cash $273.3M
Net income of $124.0M in Q1 2023 vs net loss of $21.3M in Q1 2022; collaboration revenue $150.5M (vs $0.7M).
Voyager Therapeutics has less than $2M at Silicon Valley Bank, less than 1% of total cash
Aggregate SVB accounts balance less than $2M, under 1% of total cash, equivalents and marketable securities.
Q4 2022 net loss $23.6M vs $5.7M income in Q4 2021; full-year net loss $46.4M vs $71.2M loss in 2021.
Voyager closes Neurocrine collaboration, receives $175M; Neurocrine CSO joins board
Collaboration Agreement effective; Neurocrine pays $136M upfront.
Voyager Therapeutics SVP & General Counsel Robert Hesslein to depart April 28, 2023
Robert Hesslein resigns as SVP and General Counsel effective April 28, 2023; transition period until then.
Neurocrine pays Voyager $136M upfront (net of $39M stock purchase) for GBA1 and three CNS gene therapy programs.
Voyager Therapeutics appoints Grace E. Colón, Ph.D. to board of directors, effective Jan 1, 2023
Grace E. Colón appointed as Class I director; term runs until 2025 annual meeting.
Voyager Therapeutics reports Q3 net income $17.6M; Pfizer exercises TRACER capsid option
Collaboration revenue $41.1M (vs $1.5M YoY) driven by $40M Pfizer option exercise recognition.
Pfizer exercises option on Voyager TRACER capsid for rare CNS disease; $10M fee
Pfizer exercised License Option for Voyager's novel capsid for an undisclosed rare neurologic CNS disease gene therapy program.
Voyager Therapeutics appoints new CFO, CSO, and SVP of Corporate Affairs
Peter Pfreundschuh named CFO effective Sept 19, 2022; base salary $455K, target bonus 40%, 200K option + 125K RSU.
Voyager Therapeutics prioritizes tau/GBA1/SOD1-ALS pipeline, posts Q2 net loss of $19.1M
Q2 collaboration revenue $0.7M (down from $1.4M YoY); net loss $19.1M vs $30.1M in Q2 2021.
Voyager Therapeutics appoints Catherine J. Mackey, Ph.D. to Board of Directors
Dr. Mackey appointed as Class I director effective August 15, 2022, serving until 2025 annual meeting.
Voyager Therapeutics terminates Cambridge lease and BioNTech sublease without penalty
Lease termination effective June 22, 2022; no termination fees incurred.
Glenn Pierce resigned as Interim CSO effective June 2, 2022, after serving in the role since June 2021 on a part-time basis.
Voyager Q1 net loss $21.3M, inked Novartis deal for $54M upfront
Q1 net loss $21.3M; collaboration revenue $0.7M (down from $6.5M YoY); cash $166.8M, runway into 2024.
On June 11, 2024, Voyager Therapeutics, Inc. (the “Company”) and Nathan Jorgensen entered into an employment agreement (the “Jorgensen Agreement”), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024
On May 6, 2023, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed George Scangos, Ph.D. as a director of the Company and as a member of the Science and Technology Committee of the Board, effective May 9, 2023.
the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), approved the appointment of Jude Onyia, Ph.D., to serve as a director of the Company, contingent upon and effective as of the closing
Mr. Hesslein resigned from his position of Senior Vice President and General Counsel and from any and all other positions he holds as an officer or employee of the Company or an officer, employee or director of any of its subsidiaries, effective on April 28, 2023
appointed Grace E. Colón, Ph.D. as a director of the Company and as a member of the Compensation Committee of the Board, effective January 1, 2023.
pursuant to which Mr. Pfreundschuh agreed to serve as the Chief Financial Officer of the Company, with the first date of employment to commence on September 19, 2022
On July 27, 2022, the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Catherine J. Mackey, Ph.D. as a director of the Company and as a member of both the Audit Committee and the Science and Technology Committee of the Board, effective August 15, 2022.
On June 2, 2022, Glenn Pierce, M.D., Ph.D. provided notice to Voyager Therapeutics, Inc. (“Voyager”) of his resignation as Interim Chief Scientific Officer, effective immediately (the “Pierce Transition”).
Mark Levin and Steven Paul, M.D. each requested not to be nominated for re-election to the Board when his current term expires at the Company’s 2022 annual meeting of stockholders.
Mark Levin and Steven Paul, M.D. each requested not to be nominated for re-election to the Board when his current term expires at the Company’s 2022 annual meeting of stockholders.
Appointment of Alfred Sandrock, M.D., Ph.D. as President and Chief Executive Officer
appointed Alfred Sandrock, M.D., Ph.D. as a director of the Company and as a member of both the Executive Committee and the Science and Technology Committee of the Board, effective February 7, 2022.
Max materiality 0.90 · Median 0.60 · Most common event earnings